Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKesson
Merck
Harvard Business School
Mallinckrodt

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Selumetinib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Selumetinib: Sponsors, patents, clinical trial progress

Selumetinib is an investigational drug.

There have been 88 clinical trials for Selumetinib. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Neurofibromatoses. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Cancer Research UK.

There are eighty-six US patents protecting this investigational drug and seven hundred and eighty-five international patents.

Recent Clinical Trials for Selumetinib
TitleSponsorPhase
Selumetinib Versus Carboplatin/Vincristine in Treating Patients With Newly Diagnosed or Previously Untreated NF1-Associated Low-Grade GliomaNational Cancer Institute (NCI)Phase 3
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)Merck Sharp & Dohme Corp.Phase 1
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)Merck Sharp & Dohme Corp.Phase 1

See all Selumetinib clinical trials

Clinical Trial Summary for Selumetinib

Top disease conditions for Selumetinib
Top clinical trial sponsors for Selumetinib

See all Selumetinib clinical trials

US Patents for Selumetinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Selumetinib   Start Trial Organic compositions to treat beta-catenin-related diseases Arrowhead Pharmaceuticals, Inc. (Pasadena, CA)   Start Trial
Selumetinib   Start Trial Compositions and methods for epithelial stem cell expansion and culture Massachusetts Institute of Technology (Cambridge, MA) The Brigham and Women's Hospital, Inc. (Boston, MA)   Start Trial
Selumetinib   Start Trial Compositions and methods for epithelial stem cell expansion and culture Massachusetts Institute of Technology (Cambridge, MA) The Brigham and Women's Hospital, Inc. (Boston, MA)   Start Trial
Selumetinib   Start Trial Cyclopropanamine compound and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Selumetinib   Start Trial Benzothiophene-based selective estrogen receptor downregulators The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
Selumetinib   Start Trial Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Infinity Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Selumetinib   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Selumetinib

Drugname Country Document Number Estimated Expiration Related US Patent
Selumetinib Australia 2013208720 2032-01-09   Start Trial
Selumetinib Brazil 112014016870 2032-01-09   Start Trial
Selumetinib Canada 2860676 2032-01-09   Start Trial
Selumetinib China 104302768 2032-01-09   Start Trial
Selumetinib European Patent Office 2802658 2032-01-09   Start Trial
Selumetinib Hong Kong 1205758 2032-01-09   Start Trial
Selumetinib Japan 2015503608 2032-01-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Baxter
AstraZeneca
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.